Advances in the diagnosis and treatment of hepatobiliary pancreatic (HBP) cancers, comprising liver, bile duct, and pancreatic cancers, are crucial as their incidence continues to rise globally. Historically, progress in treating HBP cancers lagged behind other common cancers such as breast and lung cancer. However, remarkable advancements over the past five years have significantly altered this landscape. For hepatocellular carcinoma (HCC) and biliary tract cancers, the introduction of immunotherapy-based regimens has led to possibly long-term survival of patients with advanced disease. The current development aim to increase cure rates through the combination of various therapeutic modalities. In pancreatic cancer, despite challenges in developing effective targeted therapies or immunotherapy, recent innovations offer hope. Novel KRAS inhibitors and vaccine therapies are promising, Collectively, these advancements represent a pivotal shift towards more effective and sustainable treatment options for patients afflicted by HBP cancers, underscoring the importance of continued research and clinical trials to further enhance patient outcomes.
